Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Malgorzata Beryt"'
Autor:
Richard J. Pietras, Dennis J. Slamon, Mark D. Pegram, Carminda O'Callaghan, Gottfried E. Konecny, Malgorzata Beryt
Publikováno v:
JNCI Journal of the National Cancer Institute. 96:739-749
Background: Trastuzumab, a humanized anti-HER2 antibody, increases the clinical benefit of first-line chemotherapy in patients with metastatic breast cancers that overexpress HER2. We characterized interactions between trastuzumab and chemotherapeuti
Autor:
Murk Pegram, Giovanni Pauletti, Malgorzata Beryt, H. Hepp, He-Jing Wang, Sugandha Dandekar, Hong-Mei Rong, Cindy A. Wilson, Margret Felber, Gottfried E. Konecny, Michael Untch, Ingo Bauerfeind, Rani Seshadri, Zuleima Aguilar, Dennis J. Slamon
Publikováno v:
JNCI Journal of the National Cancer Institute. 95:142-153
Background: HER-2/neu, which encodes a receptor tyrosine kinase, is amplified and overexpressed in 20%-25% of human breast cancers. Such tumors are often resistant to hormone therapy. Despite a general inverse association between HER-2/neu amplificat
Autor:
Michael Untch, Sandra Lude, Malgorzata Beryt, Dennis J. Slamon, Mark D. Pegram, Steffen Kahlert, Margret Felber, Hermann Hepp, Gottfried E. Konecny, Elena Langer
Publikováno v:
Breast Cancer Research and Treatment. 67:223-233
The purpose of this study was to analyze the drug interactions of paclitaxel (PTX) with epirubicin (EPI), carboplatin (CBDCA), gemcitabine (GEM) and vinorelbine (VIN) in human breast cancer cells and compare the cytotoxic activity of each drug combin
Autor:
Karo K. Arzoo, Malgorzata Beryt, Dennis J. Slamon, Richard J. Pietras, Richard S. Finn, Mark D. Pegram
Publikováno v:
Oncogene. 15:537-547
Recent studies indicate that oncogenes may be involved in determining the sensitivity of human cancers to chemotherapeutic agents. To define the effect of HER-2/neu oncogene overexpression on sensitivity to chemotherapeutic drugs, a full-length, huma
Autor:
James K. Liu, Xiaomei Bai, Lisa Turin, Malgorzata Beryt, Cathleen Brdlik, Brett Jorgensen, Juan Zhang, Ying Feng, Pei Jin, H. Michael Shepard
Publikováno v:
Molecular medicine (Cambridge, Mass.). 15(1-2)
The human epidermal growth factor (EGF) receptor (HER) family members cooperate in malignancy. Of this family, HER2 does not bind growth factors and HER3 does not encode an active tyrosine kinase. This diversity creates difficulty in creating pan-spe
Autor:
Malgorzata Beryt, J C Sarup, Peter Lindley, Francis W. Lau, H. Michael Shepard, James K. Liu, Jeffrey Higaki, Lisa Turin, Irene Ni, Juan Zhang, Cathleen Brdlik, James Rozzelle, Rajendra Kumari, Brett Jorgensen, Xiaomei Bai, Pei Jin, Susan A. Watson
Publikováno v:
Molecular cancer therapeutics. 7(10)
All four members of the human epidermal growth factor (EGF) receptor (HER) family are implicated in human cancers. Although efficacious in a subset of patients, resistance to single-targeted anti-HER therapy [i.e., cetuximab (Erbitux) and trastuzumab
Autor:
Wei-Ann, Hsueh, Amanda L, Kesner, Anne, Gangloff, Mark D, Pegram, Malgorzata, Beryt, Johannes, Czernin, Michael E, Phelps, Daniel H S, Silverman
Publikováno v:
Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 47(12)
Paclitaxel is used as a chemotherapy drug for the treatment of various malignancies, including breast, ovarian, and lung cancers. To evaluate the potential of a noninvasive prognostic tool for specifically predicting the resistance of tumors to pacli
Autor:
Anne, Gangloff, Wei-Ann, Hsueh, Amanda L, Kesner, Dale O, Kiesewetter, Betty S, Pio, Mark D, Pegram, Malgorzata, Beryt, Allison, Townsend, Johannes, Czernin, Michael E, Phelps, Daniel H S, Silverman
Publikováno v:
Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 46(11)
Paclitaxel (PAC) is widely used as a chemotherapy drug in the treatment of various malignancies, including breast, ovarian, and lung cancers. We examined the biodistribution of (18)F-fluoropaclitaxel ((18)F-FPAC) in mice with and without human breast
Autor:
Dennis J. Slamon, Melinda Epstein, Jean-Michel Vernes, He-Jing Wang, Y. Gloria Meng, Mark D. Pegram, Hermann Hepp, Kyu Hong, Michael Untch, Johnny Gutierrez, Petra Stieber, Gottfried E. Konecny, Ingo Bauerfeind, Malgorzata Beryt
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 10(5)
Purpose: Activation or overexpression of HER-2/neu is associated with up-regulation of vascular endothelial growth factor (VEGF) in human breast cancer cells in vitro. Preclinical experiments indicate that increased expression of VEGF may in part med
Autor:
Sandra Lude, Manuel Fritz, Annette Lebeau, Gottfried E. Konecny, Malgorzata Beryt, Dennis J. Slamon, Mark D. Pegram, Hermann Hepp, Margrit Felber, Michael Untch
Publikováno v:
Breast cancer research and treatment. 69(1)
Available clinical and experimental data on the effect of HER-2/neu overexpression on chemosensitivity are controversial. It was the purpose of this in vitro study to define the association between HER-2/neu overexpression and the sensitivity to the